Mutual of America Capital Management LLC lessened its holdings in shares of Axcelis Technologies, Inc. (NASDAQ:ACLS - Free Report) by 77.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,906 shares of the semiconductor company's stock after selling 16,423 shares during the period. Mutual of America Capital Management LLC's holdings in Axcelis Technologies were worth $514,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the business. Boston Trust Walden Corp purchased a new position in Axcelis Technologies in the third quarter valued at $53,099,000. Reinhart Partners LLC. raised its stake in shares of Axcelis Technologies by 64.1% during the 3rd quarter. Reinhart Partners LLC. now owns 687,608 shares of the semiconductor company's stock worth $72,096,000 after buying an additional 268,560 shares in the last quarter. Granite Investment Partners LLC purchased a new position in Axcelis Technologies in the second quarter worth $27,801,000. Boston Partners acquired a new position in Axcelis Technologies during the first quarter worth about $20,819,000. Finally, Royce & Associates LP increased its stake in Axcelis Technologies by 157.1% in the 3rd quarter. Royce & Associates LP now owns 273,671 shares of the semiconductor company's stock valued at $28,694,000 after purchasing an additional 167,235 shares in the last quarter. Institutional investors and hedge funds own 89.98% of the company's stock.
Analysts Set New Price Targets
A number of brokerages have commented on ACLS. Needham & Company LLC reiterated a "hold" rating on shares of Axcelis Technologies in a report on Friday, November 8th. B. Riley dropped their target price on shares of Axcelis Technologies from $190.00 to $165.00 and set a "buy" rating for the company in a research report on Friday, August 2nd. Finally, Benchmark lowered Axcelis Technologies from a "buy" rating to a "hold" rating in a research report on Friday, November 8th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Axcelis Technologies currently has a consensus rating of "Moderate Buy" and a consensus target price of $167.33.
View Our Latest Stock Report on ACLS
Axcelis Technologies Stock Down 1.3 %
Shares of Axcelis Technologies stock traded down $0.94 during trading on Wednesday, hitting $73.51. 376,810 shares of the stock traded hands, compared to its average volume of 638,642. The stock has a market cap of $2.39 billion, a P/E ratio of 10.87, a PEG ratio of 2.41 and a beta of 1.60. Axcelis Technologies, Inc. has a twelve month low of $69.35 and a twelve month high of $158.61. The company has a fifty day moving average price of $90.57 and a two-hundred day moving average price of $110.41. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.29 and a current ratio of 4.45.
Axcelis Technologies Profile
(
Free Report)
Axcelis Technologies, Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and Asia Pacific. The company offers high energy, high current, and medium current implanters for various application requirements.
Featured Stories
Before you consider Axcelis Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axcelis Technologies wasn't on the list.
While Axcelis Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.